Project Description

Evolution of ELN recommendations for monitoring and treatment of CML

  • Evolution of CML treatment and milestones
  • Importance of reaching early responses for long-term outcomes
  • ELN 2013 recommendations and practical considerations
    • Value of routine monitoring, at which frequency?
    • Molecular or cytogenetic monitoring, or both?
  • 2G TKI in frontline setting, since this is not approved in Brazil
  • Real world factors influencing drug choice

Dr. Gianantonio Rosti

Department of Hematology and Oncology
'L. and A. Seràgnoli' St Orsola University Hospital - Bologna